Compare Moderna, Inc. (MRNA) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Verisign, Inc. — how do they compare? Moderna, Inc. trades at $137.5 (market cap $56.02B), while Verisign, Inc. trades at $287 (market cap $25.51B). The key difference: Moderna, Inc. is far larger — about 2.2× Verisign, Inc.'s market cap, and Verisign, Inc. pays a 1.15% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VRSN | |
|---|---|---|
Market Cap | $56.02B | $25.51B |
Sector | Health | Technology |
52-Week High | $174.38 | $310.00 |
52-Week Low | $22.36 | $211.49 |
Enterprise Value | $52.17B | $26.82B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal but strong fundamentals including a 49.77% net income margin and record domain registrations. Recent Q2 2026 earnings beat estimates with EPS of $2.38, though Q4 2025 and Q2 2026 missed expectations. The stock faces headwinds from an antitrust lawsuit filed in September 2026, but institutional buying by firms like BlackRock signals confidence.
Outlook is mixed: bullish analyst consensus with a $328.50 price target suggests 16% upside, supported by AI-driven domain growth and a pending .web delegation. Risks include legal overhangs and competitive pressures. The current valuation at a P/E of 30.64 may limit near-term gains unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
